Protocol Ledger

NCT07061964 · Phase II · RECRUITING

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Interventional Phase II clinical trial protocol NCT07061964 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-25 Enrollment: 111 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07061964
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07061964
Protocol FieldVerified Registry Value
NCT IdentifierNCT07061964
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment111 participants (ESTIMATED)
Registered Start Date2025-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI